GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Revenue

Starpharma Holdings (ASX:SPL) Revenue : A$8.29 Mil (TTM As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings Revenue?

Starpharma Holdings's revenue for the six months ended in Jun. 2024 was A$1.09 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was A$8.29 Mil. Starpharma Holdings's Revenue per Share for the six months ended in Jun. 2024 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.02.

Good Sign:

Starpharma Holdings Ltd has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Starpharma Holdings was 185.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 58.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 20.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Starpharma Holdings's highest 3-Year average Revenue per Share Growth Rate was 100.00% per year. The lowest was -41.50% per year. And the median was -4.10% per year.


Starpharma Holdings Revenue Historical Data

The historical data trend for Starpharma Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Revenue Chart

Starpharma Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.03 1.80 4.68 2.94 8.29

Starpharma Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 1.09 1.85 7.20 1.09

Competitive Comparison of Starpharma Holdings's Revenue

For the Biotechnology subindustry, Starpharma Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Revenue falls into.



Starpharma Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$8.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starpharma Holdings  (ASX:SPL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Starpharma Holdings Revenue Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings Headlines

No Headlines